We are live on
!
Find out more
TCM
Tang Capital Management Portfolio holdings
AUM
$1.97B
1-Year Est. Return
125.1%
This Fund
S&P 500
This Quarter
Est. Return
+10.56%
1 Year Est. Return
+125.1%
3 Year Est. Return
+474.48%
5 Year Est. Return
+595.08%
10 Year Est. Return
+2,831.44%
AUM
$1.98B
AUM Growth
+$171M
(+9.4%)
Cap. Flow
+$109M
Cap. Flow
% of AUM
5.49%
Top 10 Holdings %
Top 10 Hldgs %
35.03%
Holding
220
New
18
Increased
34
Reduced
52
Closed
20
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Vera Therapeutics
VERA
|
+$27M |
| 2 |
MRUS
Merus
MRUS
|
+$23.5M |
| 3 |
Mettler-Toledo International
MTD
|
+$21.8M |
| 4 |
Boeing
BA
|
+$18.8M |
| 5 |
Sarepta Therapeutics
SRPT
|
+$17.9M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
DVAX
Dynavax Technologies
DVAX
|
+$40M |
| 2 |
ITCI
Intra-Cellular Therapies Inc.
ITCI
|
+$29M |
| 3 |
SLRN
ACELYRIN
SLRN
|
+$24.3M |
| 4 |
ONC
BeOne Medicines Ltd
ONC
|
+$10.1M |
| 5 |
CRISPR Therapeutics
CRSP
|
+$9.07M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 94.16% |
| 2 | Technology | 1.37% |
| 3 | Industrials | 1.32% |
| 4 | Communication Services | 1.26% |
| 5 | Consumer Discretionary | 0.8% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
176
Chevron
CVX
$366B
| $750K | 0.04% |
5,239
-458
| -8% | -$64.6K |
|
177
Puma Biotechnology
PBYI
$454M
| $686K | 0.03% |
200,000
| – | – |
|
178
FedEx
FDX
$75.4B
| $657K | 0.03% |
2,892
-309
| -10% | -$67.7K |
|
|
CNTA
179
DELISTED
Centessa Pharmaceuticals
CNTA
| $657K | 0.03% |
50,000
| – | – |
|
180
Amylyx Pharmaceuticals
AMLX
$2.54B
| $641K | 0.03% |
100,000
| – | – |
|
181
Clorox
CLX
$12.7B
| $619K | 0.03% |
5,154
-612
| -11% | -$81.7K |
|
182
Passage Bio
PASG
$14.1M
| $600K | 0.03% |
75,000
| – | – |
|
183
Kura Oncology
KURA
$850M
| $577K | 0.03% |
100,000
| – | – |
|
184
BioAtla
BCAB
$5.74M
| $544K | 0.03% |
27,482
| – | – |
|
|
ATXS
185
DELISTED
Astria Therapeutics
ATXS
| $536K | 0.03% |
100,000
| – | – |
|
186
OmniAb
OABI
$447M
| $522K | 0.03% |
300,000
| – | – |
|
187
Century Therapeutics
IPSC
$361M
| $503K | 0.03% |
900,000
| – | – |
|
188
Fortrea Holdings
FTRE
$1.75B
| $494K | 0.03% |
100,000
| – | – |
|
189
Standard BioTools
LAB
$314M
| $489K | 0.02% |
407,755
| – | – |
|
|
FLNA
190
Filana Therapeutics
FLNA
$48.1M
| $434K | 0.02% |
239,820
+39,820
| +20% | +$70.9K |
|
|
OKUR
191
OnKure Therapeutics
OKUR
$168M
| $404K | 0.02% |
169,245
-230,755
| -58% | -$605K |
|
192
Kodiak Sciences
KOD
$2.84B
| $373K | 0.02% |
100,000
| – | – |
|
193
Metagenomi Therapeutics
MGX
$46.3M
| $296K | 0.02% |
200,000
+65,022
| +48% | +$102K |
|
194
Invivyd
IVVD
$218M
| $286K | 0.01% |
400,000
| – | – |
|
195
MacroGenics
MGNX
$257M
| $265K | 0.01% |
218,856
| – | – |
|
|
LONA
196
LeonaBio Inc
LONA
$72.1M
| $181K | 0.01% |
60,000
| – | – |
|
197
Fennec Pharmaceuticals
FENC
$402M
| $170K | 0.01% |
+20,527
| New | +$140K |
|
198
Seres Therapeutics
MCRB
$48.4M
| $155K | 0.01% |
13,921
+3,726
| +37% | +$32.8K |
|
|
ACTU
199
Actuate Therapeutics
ACTU
$26.3M
| $32K | ﹤0.01% |
+5,243
| New | +$45.8K |
|
200
Galectin Therapeutics
GALT
$348M
| $27.2K | ﹤0.01% |
+12,913
| New | +$19.3K |
|
Similar funds
HA
NIM
RMCM
FC
SC
CAM
BC
FFH
Tang Capital Management's Q2 2025 Portfolio in Review
As of Q2 2025, Tang Capital Management held 220 positions worth $1.98B, up 9.4% from $1.81B the previous quarter. Its ten largest holdings account for 35% of the portfolio.
Tang Capital Management deployed $109M of net new capital in Q2 2025, opening 18 new positions and adding to 34 existing holdings. Its largest new stake was Mettler-Toledo International: 19,500 shares worth $22.9M.
By sector, the portfolio is most concentrated in Healthcare at 94% of assets, down from 95% a quarter earlier, followed by Technology and Industrials.
On the sell side, the largest reduction was Dynavax Technologies, an estimated $40M trimmed.
- Tang Capital Management's largest Q2 2025 buy was Mettler-Toledo International: 19,500 shares worth $22.9M.
- Tang Capital Management added most to Vera Therapeutics in Q2 2025, an estimated $27M increase.
- Tang Capital Management's biggest Q2 2025 reduction was Dynavax Technologies, cutting an estimated $40M.
- Tang Capital Management fully exited Intra-Cellular Therapies Inc. in Q2 2025, selling an estimated $29M.
- Tang Capital Management's ten largest holdings make up 35% of its $1.98B portfolio in Q2 2025.
- Tang Capital Management opened 18 new positions and closed 20 in Q2 2025.
- Tang Capital Management's portfolio value rose 9.4% quarter-over-quarter to $1.98B.
Based on Tang Capital Management's 13F filing for Q2 2025, filed 14 Aug 2025.